alendronate has been researched along with Hyperparathyroidism, Secondary in 9 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Hyperparathyroidism, Secondary: Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether secondary hyperparathyroidism (HPTH) due to hypovitaminosis D affects bone mineral density (BMD) response to alendronate (ALN) in elderly women with osteoporosis." | 9.12 | Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. ( Barone, A; Bianchi, G; Girasole, G; Giusti, A; Palummeri, E; Pioli, G; Pizzonia, M; Razzano, M, 2007) |
| "To determine whether secondary hyperparathyroidism (HPTH) due to hypovitaminosis D affects bone mineral density (BMD) response to alendronate (ALN) in elderly women with osteoporosis." | 5.12 | Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. ( Barone, A; Bianchi, G; Girasole, G; Giusti, A; Palummeri, E; Pioli, G; Pizzonia, M; Razzano, M, 2007) |
| " In the present study, we aimed to examine the efficacy and safety of alendronate (ALN) and teriparatide (TPD) for treating bone disorder in late-stage CKD with pre-existing secondary hyperparathyroidism using a rat model of CKD." | 3.85 | Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. ( Hamano, H; Hiratsuka, S; Iwasaki, N; Kameda, Y; Kanehira, Y; Kimura-Suda, H; Ota, M; Sato, D; Shimizu, T; Takahata, M, 2017) |
| "In a woman with postmenopausal osteoporosis, the infusion of alendronate (7." | 1.29 | The effect of alendronate on renal tubular reabsorption of phosphate. ( Gertz, B; Kahn, S; Kanis, JA; McCloskey, EV; O'Doherty, DP; Vasikaran, SD, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ota, M | 1 |
| Takahata, M | 1 |
| Shimizu, T | 1 |
| Kanehira, Y | 1 |
| Kimura-Suda, H | 1 |
| Kameda, Y | 1 |
| Hamano, H | 1 |
| Hiratsuka, S | 1 |
| Sato, D | 1 |
| Iwasaki, N | 1 |
| Benhalima, K | 1 |
| Katrien, B | 1 |
| Mertens, A | 1 |
| Ann, M | 1 |
| Van den Bruel, A | 1 |
| Annick, Vd | 1 |
| Laga, K | 1 |
| Katrien, L | 1 |
| Vanderschueren, D | 1 |
| Dirk, V | 1 |
| Samson, I | 1 |
| Ignace, S | 1 |
| Van Damme, B | 1 |
| Boudewijin, VD | 1 |
| Bouillon, R | 1 |
| Roger, B | 1 |
| Resnick, J | 1 |
| Gupta, N | 1 |
| Wagner, J | 1 |
| Costa, G | 1 |
| Cruz, RJ | 1 |
| Martin, L | 1 |
| Koritsky, DA | 1 |
| Perera, S | 1 |
| Matarese, L | 1 |
| Eid, K | 1 |
| Schuster, B | 1 |
| Roberts, M | 1 |
| Greenspan, S | 1 |
| Abu-Elmagd, K | 1 |
| Jain, SK | 1 |
| Roy, SP | 1 |
| Nagi, ON | 1 |
| Torregrosa, JV | 1 |
| Durán, CE | 1 |
| Barros, X | 1 |
| Blasco, M | 1 |
| Arias, M | 1 |
| Cases, A | 1 |
| Campistol, JM | 1 |
| Barone, A | 1 |
| Giusti, A | 1 |
| Pioli, G | 1 |
| Girasole, G | 1 |
| Razzano, M | 1 |
| Pizzonia, M | 1 |
| Palummeri, E | 1 |
| Bianchi, G | 1 |
| Vasikaran, SD | 1 |
| O'Doherty, DP | 1 |
| McCloskey, EV | 1 |
| Gertz, B | 1 |
| Kahn, S | 1 |
| Kanis, JA | 1 |
| Ikeda, K | 1 |
| Kawaguchi, Y | 1 |
| Nakayama, M | 1 |
| Yamamoto, H | 1 |
| Osaka, N | 1 |
| Takeyama, H | 1 |
| Hosoya, T | 1 |
| Thompson, DD | 1 |
| Seedor, JG | 1 |
| Grasser, W | 1 |
| Rosenblatt, M | 1 |
| Rodan, GA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quantifying Fatigue of the Respiratory and Swallowing Musculature in Patients With Amyotrophic Lateral Sclerosis[NCT04468191] | 0 participants (Actual) | Interventional | 2021-02-10 | Withdrawn (stopped due to COVID-19 pandemic restrictions for data collection) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for alendronate and Hyperparathyroidism, Secondary
| Article | Year |
|---|---|
Successful treatment of calcific uraemic arteriolopathy with bisphosphonates.
Topics: Aged; Alendronate; Alkaline Phosphatase; Arterioles; Calciphylaxis; Calcium; Comorbidity; Diphosphon | 2012 |
Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitrio | 2007 |
7 other studies available for alendronate and Hyperparathyroidism, Secondary
| Article | Year |
|---|---|
Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Remodeling; Disease Models, Animal; Dru | 2017 |
A brown tumor after biliopancreatic diversion for severe obesity.
Topics: Alendronate; Biliopancreatic Diversion; Bone Density; Calcifediol; Calcium; Female; Humans; Hyperpar | 2009 |
Skeletal integrity and visceral transplantation.
Topics: Adult; Alendronate; Biomarkers; Bone Density; Female; Fractures, Bone; Humans; Hyperparathyroidism, | 2010 |
Alendronate induced femur fracture complicated with secondary hyperparathyroidism.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Humans; Hyperparathy | 2011 |
The effect of alendronate on renal tubular reabsorption of phosphate.
Topics: Absorption; Aged; Alendronate; Calcium; Diphosphonates; Female; Glomerular Filtration Rate; Homeosta | 1994 |
Novel usage of alendronate to prevent profound hypocalcemia immediately after parathyroidectomy in patients with severe secondary hyperparathyroidism.
Topics: Alendronate; Calcium; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Male; Middle Aged; Parat | 1999 |
Effect of alendronate (bisphosphonate) in animal models of hyperparathyroidism.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Calcium; Diphosphonates; Disease Models, Animal | 1991 |